Vascugen, founded in 2018, is a private, pre-clinical stage biotech advancing a novel iPSC-derived vasculogenic cell therapy platform. The company's technology aims to directly restore blood flow via vasculogenesis, differentiating it from failed angiogenic approaches. With a focus on high-unmet-need ischemic diseases and a potential application in tissue engineering, Vascugen is translating foundational research from its scientific founder into therapeutic candidates.
Proprietary differentiation of human induced pluripotent stem cells (iPSCs) into engineered vasculogenic cells capable of direct de novo blood vessel formation (vasculogenesis).
Funding History
1
Total raised:$25M
Series A$25MEli Lilly and Company
Opportunities
Large, growing patient populations with severe ischemic diseases (e.g., CLI, Diabetic Retinopathy) have limited treatment options, creating a significant market for a successful regenerative therapy.
The company's scalable iPSC platform also presents a secondary opportunity in the emerging tissue engineering and 3D bioprinting sector as a source of vascular cells.
Risk Factors
High scientific risk that promising preclinical data will not translate to human efficacy and safety.
Significant regulatory and manufacturing challenges associated with novel, iPSC-derived cell therapies.
The company is pre-revenue and will require substantial additional capital to advance through clinical development.
Competitive Landscape
Competition includes other cell therapy approaches (e.g., mesenchymal stem cells), gene therapies, and medical devices for revascularization. Vascugen differentiates by targeting direct vasculogenesis (vs. indirect angiogenesis) and using a scalable, consistent iPSC manufacturing platform. In tissue engineering, it would compete with other cell sourcing technologies.
